Nalaganje...
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
Treatment of advanced (metastatic) non-small-cell lung cancer (NSCLC) is currently mainly based on immunotherapy with antibodies against PD-1 or PD-L1, alone, or in combination with chemotherapy. In locally advanced NSCLC and in early resected stages, immunotherapy is also employed. Tumor PD-L1 expr...
Shranjeno v:
| izdano v: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7352732/ https://ncbi.nlm.nih.gov/pubmed/32516941 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12061475 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|